Literature DB >> 8818371

Prediction of ECT response: validation of a refined sign-based (CORE) system for defining melancholia.

I Hickie1, C Mason, G Parker, H Brodaty.   

Abstract

BACKGROUND: The clinical validity of melancholia has been argued on the basis of its capacity to predict response to electroconvulsive therapy (ECT). We have argued that a sign-based (CORE) rating system of psychomotor disturbance can identify patients with melancholia. Therefore, the clinical validity of the CORE system was tested here in terms of its capacity to predict response to ECT.
METHOD: The response of 81 patients with primary affective disorders to an individualised course of ECT was investigated. CORE scores and other clinical predictors were evaluated in terms of their capacity to predict effect size changes in symptoms and disability.
RESULTS: CORE scores predicted ECT response, as did the presence of psychotic features. The combination of marked psychomotor change (high CORE scores) and psychotic features predicted the best response to ECT.
CONCLUSION: This study supports the clinical validity of the CORE system for diagnosing melancholia.

Entities:  

Mesh:

Year:  1996        PMID: 8818371     DOI: 10.1192/bjp.169.1.68

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

Review 1.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

Review 2.  Neuromodulation therapies for geriatric depression.

Authors:  Verònica Gálvez; Kerrie-Anne Ho; Angelo Alonzo; Donel Martin; Duncan George; Colleen K Loo
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

3.  Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy.

Authors:  Gavin Rush; Aoife O'Donovan; Laura Nagle; Catherine Conway; AnnMaria McCrohan; Cliona O'Farrelly; James V Lucey; Kevin M Malone
Journal:  J Affect Disord       Date:  2016-06-17       Impact factor: 4.839

4.  Grey matter volume increase following electroconvulsive therapy in patients with late life depression: a longitudinal MRI study.

Authors:  Filip Bouckaert; François-Laurent De Winter; Louise Emsell; Annemieke Dols; Didi Rhebergen; Martien Wampers; Stefan Sunaert; Max Stek; Pascal Sienaert; Mathieu Vandenbulcke
Journal:  J Psychiatry Neurosci       Date:  2016-03       Impact factor: 6.186

5.  [Vagus nerve stimulation, repetitive transcranial magnetic stimulation, and electroconvulsive therapy in the treatment of depressive disorders].

Authors:  M Bajbouj; I Heuser
Journal:  Nervenarzt       Date:  2005-01       Impact factor: 1.214

6.  Clinical variables as predictors of response to electroconvulsive therapy in endogenous depression.

Authors:  N Gupta; A Avasthi; P Kulhara
Journal:  Indian J Psychiatry       Date:  2000-01       Impact factor: 1.759

Review 7.  Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy.

Authors:  Shawn M McClintock; Jimmy Choi; Zhi-De Deng; Lawrence G Appelbaum; Andrew D Krystal; Sarah H Lisanby
Journal:  J ECT       Date:  2014-06       Impact factor: 3.635

8.  Predictors of response to electro-convulsive therapy in major depression.

Authors:  B Sivaprakash; R Chandrasekaran; A Sahai
Journal:  Indian J Psychiatry       Date:  2000-04       Impact factor: 1.759

9.  Symptom predictors of response to electroconvulsive therapy in older patients with treatment-resistant depression.

Authors:  Keiichiro Tominaga; Mioto Okazaki; Hisashi Higuchi; Itaru Utagawa; Etsuko Nakamura; Noboru Yamaguchi
Journal:  Int J Gen Med       Date:  2011-07-08

Review 10.  Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities.

Authors:  Renana Eitan; Bernard Lerer
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.